Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration
- PMID: 17191188
- DOI: 10.1177/112067210601600607
Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration
Abstract
Purpose: Choroidal neovascularization associated with age-related macular degeneration is the primary cause of blindness in the elderly in developed countries, due to a number of pathogenic effects, including angiogenesis, cell-mediated inflammation, leukocyte adhesion and extravasation, and matrix remodeling.
Methods: By producing photochemical effects at the site of target tissue (lesion), photodynamic therapy (PDT) can induce vascular damage and blood flow stasis, leading to occlusion of vascularization and lesion leakage.
Results: PDT with verteporfin (Visudyne, Novartis) has been shown to be safe and effective in reducing the risk of vision loss in patients with classic containing subfoveal CNV and occult with no classic CNV. However, in predominantly occult CNV, the treatment may be most effective in smaller lesions, and less in larger lesions. Most important, visual acuity rarely is improved.
Conclusions: Pilot studies and large case series suggest that a combination of PDT and intravitreal triamcinolone acetonide has the potential to improve visual outcomes and reduce the need for additional treatments. Randomized, prospective clinical trials are underway to confirm the efficacy and safety of this novel treatment modality.
Similar articles
-
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.Curr Drug Targets. 2011 Feb;12(2):149-72. doi: 10.2174/138945011794182746. Curr Drug Targets. 2011. PMID: 20887246 Review.
-
Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.Ophthalmology. 2007 Dec;114(12):2183-9. doi: 10.1016/j.ophtha.2007.02.013. Ophthalmology. 2007. PMID: 18054638 Clinical Trial.
-
Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.Am J Ophthalmol. 2006 Jul;142(1):10-16. doi: 10.1016/j.ajo.2006.02.048. Am J Ophthalmol. 2006. PMID: 16815246
-
Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.Ophthalmology. 2006 Jan;113(1):14-22. doi: 10.1016/j.ophtha.2005.09.002. Epub 2005 Dec 19. Ophthalmology. 2006. PMID: 16360209
-
Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.Retina. 2005 Feb-Mar;25(2):119-34. doi: 10.1097/00006982-200502000-00002. Retina. 2005. PMID: 15689800 Review.
Cited by
-
Combination of photodynamic therapy and immunomodulation: current status and future trends.Med Res Rev. 2008 Jul;28(4):632-44. doi: 10.1002/med.20121. Med Res Rev. 2008. PMID: 18161883 Free PMC article. Review.
-
Combination therapy for choroidal neovascularisation.Drugs Aging. 2007;24(12):979-90. doi: 10.2165/00002512-200724120-00002. Drugs Aging. 2007. PMID: 18020531
-
Therapeutic Modalities of Exudative Age-related Macular Degeneration.Med Arch. 2014 Jun;68(3):204-208. doi: 10.5455/medarh.2014.68.204-208. Epub 2014 May 31. Med Arch. 2014. PMID: 25568535 Free PMC article. Review.
-
Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy.Graefes Arch Clin Exp Ophthalmol. 2008 Mar;246(3):339-44. doi: 10.1007/s00417-007-0667-5. Epub 2007 Sep 6. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 17805556
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical